|
Asthma
|
|
0.710 |
GeneticVariation
|
BEFREE |
ICSNPathway analysis identified four candidate causal SNPs, four genes, and 21 candidate causal pathways, which in total provided four hypothetical biologic mechanisms: (1) rs7192 (nonsynonymous coding) to HLA-DRA to 21 pathways, such as, the role of eosinophils in the chemokine network of allergy, Th1/Th2 differentiation, and asthma (nominal p ≤ 0.001, FDR p ≤ 0.01); (2) rs20541 (nonsynonymous coding) to IL13 to asthma and cytokines and inflammatory response (nominal p<0.001, FDR p ≤ 0.008); (3) rs1058808 (frameshift coding) to ERBB2 to transmembrane receptor activity (nominal p=0.001, FDR p=0.01); (4) rs17350764 (nonsynonymous coding (deleterious)) to OR52J3 to transmembrane receptor activity (nominal p=0.001, FDR p=0.01).
|
23200760 |
2013 |
|
Asthma
|
|
0.710 |
GeneticVariation
|
GWASDB |
Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations.
|
21804549 |
2011 |
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
The Pro1170Ala polymorphism is one of the most common polymorphisms of human epidermal growth factor receptor 2 (HER2) and may affect the clinical outcome in breast cancer.
|
28529593 |
2017 |
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
The Pro1170Ala polymorphism is one of the most common polymorphisms of human epidermal growth factor receptor 2 (HER2) and may affect the clinical outcome in breast cancer.
|
28529593 |
2017 |
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
The underlying link between the Ala1170Pro SNP and HER2 positivity is not known, nor is the significance of HER2 overexpression and loss of heterozygosity in breast cancer.
|
26773371 |
2016 |
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
The underlying link between the Ala1170Pro SNP and HER2 positivity is not known, nor is the significance of HER2 overexpression and loss of heterozygosity in breast cancer.
|
26773371 |
2016 |
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
HER2 rs1058808 and rs2517956 polymorphisms are associated with its protein expression in breast cancer.
|
26323365 |
2015 |
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
HER2 rs1058808 and rs2517956 polymorphisms are associated with its protein expression in breast cancer.
|
26323365 |
2015 |
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
ERBB2 Ala1170Pro was not associated with breast cancer susceptibility.
|
23900832 |
2013 |
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
ERBB2 Ala1170Pro was not associated with breast cancer susceptibility.
|
23900832 |
2013 |
|
HER2-positive carcinoma of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
This study demonstrates that only the Ala1170Pro polymorphism is associated with prognostic factors in HER2-positive breast cancer patients.
|
27788409 |
2016 |
|
HER2-positive carcinoma of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
In a retrospective cohort study of 237 women with non-metastatic HER2-positive breast cancer treated with trastuzumab, traditional risk factors were assessed by review of medical records, alcohol use by an administered questionnaire to women (n=132), and HER2 polymorphisms (Ile655Val and Ala1170Pro) using TaqMan assays (n=73).
|
23749910 |
2013 |
|
Malignant tumor of cervix
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Conclusions:</b> Our results suggested that the combination of <i>HER2</i> rs1136201and rs1058808 was significantly associated with the susceptibility of CCa.
|
30719131 |
2019 |
|
Stomach Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Increased risk for GC was observed under the dominant inheritance model for the rs2643194 TT or CT genotypes with an OR of 2.75 (95%CI 1.12-6.75, P=0.023); the rs2934971 TT or GT genotypes with an OR of 2.41 (95%CI 1.01-5.76, P=0.043), and the rs1058808 GG or CG genotypes with an OR of 2.21 (95%CI 1.00-4.87, P=0.046).
|
31116314 |
2019 |
|
Cervix carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Conclusions:</b> Our results suggested that the combination of <i>HER2</i> rs1136201and rs1058808 was significantly associated with the susceptibility of CCa.
|
30719131 |
2019 |
|
cervical cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Conclusions:</b> Our results suggested that the combination of <i>HER2</i> rs1136201and rs1058808 was significantly associated with the susceptibility of CCa.
|
30719131 |
2019 |
|
Malignant neoplasm of stomach
|
|
0.010 |
GeneticVariation
|
BEFREE |
Increased risk for GC was observed under the dominant inheritance model for the rs2643194 TT or CT genotypes with an OR of 2.75 (95%CI 1.12-6.75, P=0.023); the rs2934971 TT or GT genotypes with an OR of 2.41 (95%CI 1.01-5.76, P=0.043), and the rs1058808 GG or CG genotypes with an OR of 2.21 (95%CI 1.00-4.87, P=0.046).
|
31116314 |
2019 |
|
Eczema
|
|
0.010 |
GeneticVariation
|
BEFREE |
The CC genotype of <i>CDKAL1</i> had significantly increased risk of AD (OR, 2.16; 95% CI, 1.0~4.6; <i>p</i>=0.0475). rs1058808</span> had no correlation with AD.
|
29853740 |
2018 |
|
Dermatitis, Atopic
|
|
0.010 |
GeneticVariation
|
BEFREE |
The CC genotype of <i>CDKAL1</i> had significantly increased risk of AD (OR, 2.16; 95% CI, 1.0~4.6; <i>p</i>=0.0475). rs1058808</span> had no correlation with AD.
|
29853740 |
2018 |
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
In our previous study, we demonstrated that rs61552325 (Pro1140Ala) located in ERBB2 is strongly correlated to prostate cancer.
|
28422721 |
2017 |
|
HER2-negative breast cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
The results of the present study suggest that patients with HER2-negative breast cancer with the HER2 Pro1170Ala polymorphism variant exhibit a decreased survival outcome.
|
28529593 |
2017 |
|
Malignant neoplasm of prostate
|
|
0.010 |
GeneticVariation
|
BEFREE |
In our previous study, we demonstrated that rs61552325 (Pro1140Ala) located in ERBB2 is strongly correlated to prostate cancer.
|
28422721 |
2017 |
|
Mammary Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
However, we found significant differences in the distribution of Ile655Val (p = 0.03) and Ala1170Pro (p = 0.01) genotypes between normal breast and breast tumor tissues.
|
27788409 |
2016 |
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Ala1170Pro polymorphism in normal breast tissue was associated with age at diagnosis (p = 0.007), tumor size (p = 0.004) and lymphovascular invasion (p = 0.06).
|
27788409 |
2016 |
|
Tumor Cell Invasion
|
|
0.010 |
GeneticVariation
|
BEFREE |
Ala1170Pro polymorphism in normal breast tissue was associated with age at diagnosis (p = 0.007), tumor size (p = 0.004) and lymphovascular invasion (p = 0.06).
|
27788409 |
2016 |